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ardiovascular Magnetic
esonance in Clinically
uspected Cardiac Amyloidosis
iagnostic Value of a Typical
attern of Late Gadolinium Enhancement*
ouise E. J. Thomson, MBCHB, FRACP
os Angeles, California
ate gadolinium enhancement (LGE) cardiovascular magnetic
esonance (CMR) imaging is a tool for noninvasive evaluation
f myocardial viability that has the advantage over other
maging techniques of being able to directly visualize nonviable
yocardium with excellent contrast and spatial resolution. In
ddition to use in patients with coronary artery disease, this
maging technique has diagnostic value in the setting of
onischemic cardiomyopathy.
See page 1022
Variable patterns of LGE have been described in a wide
ariety of cardiomyopathies. These patterns are usually quite
istinct from LGE seen after myocardial infarction and may
ven be disease specific. Mid-myocardial enhancement is
ound in hypertrophic cardiomyopathy at the site of collagen
eposition (1), and small patches of predominantly subepicar-
ial enhancement may be seen with acute myocarditis (2).
ence, CMR is a tool for differentiation between ischemic and
onischemic cardiomyopathy and for identification of disease-
pecific patterns of enhancement. Going beyond diagnosis,
here is interest in comparing the pattern and extent of LGE
ith patient risk and outcome in nonischemic cardiomyopa-
hies. For example, the presence of mid-myocardial LGE has
een associated with increased rates of adverse events and
orse outcomes in dilated cardiomyopathy (3).
In this issue of the Journal, Vogelsberg et al. (4) describe
he use of LGE-CMR in comparison to myocardial biopsy
or diagnosis of cardiac amyloidosis in a clinically routine
etting. The authors conclude that LGE-CMR can be used
or diagnosis of cardiac amyloidosis in patients presenting with
iastolic heart failure and suggest that cardiac amyloidosis may
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thec
merican College of Cardiology.
From the Cedars Sinai Medical Center, Los Angeles, California.ccur more frequently in the absence of systemic amyloid
isease than currently suspected.
Amyloidosis is the extracellular accumulation of fibrillary
roteins, certain forms of which may involve the heart.
arly detection of cardiac involvement is desirable to opti-
ize survival through aggressive treatments. In immuno-
lobulin light-chain and transthyretin-related amyloidosis,
he presence of cardiac involvement is a major factor
nfluencing both prognosis and treatment options.
Echocardiography is commonly used to screen for the
resence of cardiac involvement in systemic disease, but defin-
tive diagnosis of cardiac involvement hinges on the “gold
tandard” of endocardial biopsy. Cardiac involvement can be
he presenting feature of systemic amyloidosis or the sole
eature of disease in wild-type transthyretin-related amyloid-
sis (senile cardiac amyloidosis). In the absence of systemic
isease, or when left ventricular hypertrophy from other causes
xists, the differentiation of cardiac amyloidosis from other
auses of restrictive cardiomyopathy by echocardiography may
e challenging.
Nuclear techniques have been used for the noninvasive
etection of cardiac amyloidosis. The 2 main types of
adiolabeled tracers studied are bone tracers, particularly
9mTc-pyrophosphate and 123I-labeled serum amyloid P
rotein (SAP). Scintigraphic features associated with
ardiac amyloidosis are influenced by the type of protein
eposition, the choice of radionuclide tracer, and the
xtent of disease. Bone tracer data are extensive, with
9mTc-pyrophosphate most widely studied, but sensitivity
ppears limited; binding is nonspecific for amyloid type and
ot quantifiable. 123I-labeled SAP binds to all types of
myloid and is retained in the body in proportion to amyloid
eposition, permitting noninvasive monitoring of amyloid
egression during therapy (5).
The presence of LGE in cardiac amyloidosis has been
reviously reported. Perugini et al. (6) described CMR of a
elected group of 21 patients with a “definite diagnosis” of
ardiac amyloidosis. They found LGE in 16 of 21 patients,
ith no apparent relationship between LGE and clinical,
unctional, or histologic characteristics. In the same year,
aceira et al. (7) published CMR findings in a selected
roup of 29 patients with echocardiographic criteria for
ardiac amyloidosis in the setting of confirmed systemic
myloidosis. The CMR protocol was adjusted during this
tudy, owing to the appreciation of abnormal gadolinium
inetics in these patients. Overall, 20 of 29 patients had
GE, and the pattern was subendocardial and global in all
ases.
Vogelsberg et al. (4) describe the correlation between
GE-CMR and cardiac biopsy in a group of 33 patients
resenting with diastolic heart failure in combination with
ither myocardial hypertrophy (n  24) and/or other
onditions often associated with cardiac amyloidosis (n 
8). Unlike previous reports of LGE in patients with known
ardiac amyloidosis, this study describes an experience that
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Editorial Comment March 11, 2008:1031–2s taken from routine clinical practice and compares the
iagnostic performance of LGE-CMR with biopsy.
In their population, a “typical pattern” of circumferential
ubendocardial LGE was observed in 12 of 15 patients with
ubsequent biopsy-proven cardiac amyloidosis. The agree-
ent between LGE-CMR and biopsy was optimized by the
outine sampling of both the right and left ventricles and the
act that cardiac biopsy was guided by the location of
bnormalities on CMR. This circumstance could be con-
idered a source of bias in a study that seeks to compare a
oninvasive imaging test with a gold standard, as it can be
ypothesized that a biopsy performed blinded to CMR
ndings and limited to the right ventricular side of the
nterventricular septum would have resulted in less accurate
ampling of diseased myocardium and thus a higher “false
ositive” rate of CMR. However, 2 points can be made in
efense of the approach taken. First, the authors aim to
escribe the performance of CMR in a “clinical routine
etting” and, with routine practice, the results of noninvasive
maging are available before biopsy. Second, by virtue of this
tudy design, the authors have demonstrated that CMR can
uide cardiac biopsy in suspected cardiac amyloidosis, as
een by the excellent correlation between imaging and
istologic abnormalities. This is the same approach taken by
his group in its previous report of CMR for diagnosis of
cute myocarditis (2), where biopsy was also guided by
GE-CMR.
This study does not suggest that CMR should replace
ardiac biopsy; however, a “typical pattern” of LGE may be
ufficient to allow an assumption that a patient probably has
ardiac amyloidosis as the cause for diastolic heart failure.
iopsy may be required to define the type of amyloidosis but
an potentially be obtained from extracardiac tissue, obviating
he need for higher risk myocardial biopsy. There were 3
atients without the typical pattern of LGE-CMR in whom
ardiac biopsy demonstrated amyloid protein. The authors
uggest that CMR features may not be seen early in cardiac
myloidosis or may occasionally be atypical. With respect to
linical management, cases such as this will require cardiac
iopsy for diagnosis.
Another point of interest with this study is the observa-
ion that 11 of 15 patients diagnosed with cardiac amyloid-
sis had cardiac involvement as a first manifestation of
isease. Cardiac involvement has been considered as a late
anifestation of systemic amyloidosis, but this may be in
art related to limited sensitivity and specificity of echocar-iographic and nuclear techniques and late appearance of
ymptoms relative to cardiac disease burden.
It appears that LGE-CMR is a new, noninvasive means
f identifying patients with cardiac amyloidosis that has the
otential to reshape the current understanding of the natural
istory of systemic amyloidosis. Is it as easy as recognizing
hite from black? Not quite: the performance of LGE-
MR in cardiac amyloidosis requires understanding of the
umerous variables that influence image quality, most im-
ortantly, the altered gadolinium kinetics with amyloidosis
nd the likelihood of very diffuse involvement of the
yocardium—points that these authors clearly appreciate
nd elegantly illustrate.
Further study of LGE-CMR in cardiac amyloidosis is
eeded to define the relationship between the CMR appear-
nce and the histologic type of amyloidosis, the changing
ardiac burden of disease with treatment, and, possibly, the risk
f disease-related complications such as arrhythmia. With this
ublication, there is evidence to suggest that LGE-CMR has
linical utility for the noninvasive detection of cardiac amyloid-
sis in patients presenting with diastolic heart failure.
eprint requests and correspondence:Dr. Louise E. J. Thomson, 8700
everly Boulevard, Room M-335, Cedars Sinai Medical Center, Los
ngeles, California 90048. E-mail: louise.thomson@cshs.org.
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